Alagille syndrome

Search Trials
Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
Status:
Enrolling by invitation
Last Changed:
Mar 10, 2022
First Changed:
Sep 3, 2021
Disease(s):
Alagille Syndrome
Intervention(s):
Odevixibat
Rare Disease Patient Registry & Natural History Study – Coordination of Rare Diseases at Sanford
Status:
Recruiting
Last Changed:
Dec 15, 2021
First Changed:
Feb 15, 2013
Disease(s):
Rare Disorders
Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)
Status:
Completed
Last Changed:
Jul 14, 2021
First Changed:
Jun 11, 2014
Disease(s):
Alagille Syndrome
Intervention(s):
LUM001 (Maralixibat)Placebo
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Status:
Withdrawn
Last Changed:
Jul 2, 2017
First Changed:
Nov 7, 2010
Disease(s):
Lymphoma
Intervention(s):
RO4929097Dexamethasone
A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).
Status:
Recruiting
Last Changed:
May 13, 2022
First Changed:
Jan 28, 2021
Disease(s):
Progressive Familial Intrahepatic Cholestasis
Intervention(s):
Maralixibat

Connect. Empower. Inspire.